3-[(methyl)(piperidin-4-yl)amino]propan-1-ol | 793660-70-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-[(methyl)(piperidin-4-yl)amino]propan-1-ol
• 英文别名: 3-[Methyl(piperidin-4-yl)amino]propan-1-ol
• CAS: 793660-70-5
• 化学式: C₉H₂₀N₂O
• mdl: MFCD12086828
• 分子量: 172.271
• InChiKey: RSMGBDMEDZHITB-UHFFFAOYSA-N

物化性质

• 沸点：
  300.7±32.0 °C(Predicted)
• 密度：
  1.00±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-[(methyl)(piperidin-4-yl)amino]propan-1-ol 、 2-chloro-N-(4-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 正丁醇 为溶剂， 反应 18.0h， 生成 3-[(1-{4-[(4-Chlorophenyl)amino]-6,7-dimethoxyquinazolin-2-yl}piperidin-4-yl)(methyl)amino]propan-1-ol
  参考文献：
  名称：

  Potent CCR4 antagonists: Synthesis, evaluation, and docking study of 2,4-diaminoquinazolines

  摘要：

  A series of CC chemokine receptor-4 (CCR4) antagonists were examined in a previous report in an attempt to improve metabolic stability in human liver microsomes. In this study, the cycloheptylamine moiety of N-cycloheptyl-6,7-dimethoxy-2-(4-pyrrolidin-1-ylpiperidin-1-yl)quinazolin-4-amine 1 was replaced with the p-chloroaniline moiety, and the resulting compound, N-(4-chlorophenyl)-6,7-dimethoxy-2-(4-pyrrolidin-1-ylpiperidin-1-yl)quinazolin-4-amine (8c), retained its potency ([S-35]GTP gamma S-binding inhibition and CCL22-induced chemotaxis in humans/mice). Based on the structure-activity relationships (SAR), a homology model was constructed for CCR4 to explain the binding mode of 8c. Overall, there was good agreement between the docking pose of the CCR4 homology model and the human [S-35] GTP gamma S assay results. Administration of 8c in a murine model of acute dermatitis showed anti-inflammatory activity (oxazolone-induced contact hypersensitivity test). (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.07.062
• 作为产物：
  描述：

  tert-butyl 4-[3-hydroxypropyl(methyl)amino]piperidine-1-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 12.0h， 以2.11 g的产率得到3-[(methyl)(piperidin-4-yl)amino]propan-1-ol
  参考文献：
  名称：

  Potent CCR4 antagonists: Synthesis, evaluation, and docking study of 2,4-diaminoquinazolines

  摘要：

  A series of CC chemokine receptor-4 (CCR4) antagonists were examined in a previous report in an attempt to improve metabolic stability in human liver microsomes. In this study, the cycloheptylamine moiety of N-cycloheptyl-6,7-dimethoxy-2-(4-pyrrolidin-1-ylpiperidin-1-yl)quinazolin-4-amine 1 was replaced with the p-chloroaniline moiety, and the resulting compound, N-(4-chlorophenyl)-6,7-dimethoxy-2-(4-pyrrolidin-1-ylpiperidin-1-yl)quinazolin-4-amine (8c), retained its potency ([S-35]GTP gamma S-binding inhibition and CCL22-induced chemotaxis in humans/mice). Based on the structure-activity relationships (SAR), a homology model was constructed for CCR4 to explain the binding mode of 8c. Overall, there was good agreement between the docking pose of the CCR4 homology model and the human [S-35] GTP gamma S assay results. Administration of 8c in a murine model of acute dermatitis showed anti-inflammatory activity (oxazolone-induced contact hypersensitivity test). (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.07.062

文献信息

• Benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions
  申请人：——

  公开号：US20030105137A1

  公开（公告）日：2003-06-05

  Disclosed are carboxamide-substituted benzimidazole derivatives of general formula (I) 1 wherein the groups X, R 1 , R 2 , R 3 and R 4 may have the meanings given in the claims and specification, processes for preparing them and the use of carboxamide-substituted benzimidazole derivatives as pharmaceutical compositions, particularly as pharmaceutical compositions with a tryptase-inhibiting activity.

  本发明涉及一般式（I）的羧酰胺取代苯并咪唑衍生物，其中X、R1、R2、R3和R4基团可以具有权利要求和说明书中给出的含义，制备它们的过程以及将羧酰胺取代苯并咪唑衍生物用作制药组合物，特别是作为具有胰蛋白酶抑制活性的制药组合物。
• GAS CAPTURE PROCESS
  申请人：Yang Qi

  公开号：US20140127103A1

  公开（公告）日：2014-05-08

  A process for the capture of CO 2 from gas streams, the process including contacting a CO 2 containing gas stream with a compound including: a primary or non-sterically hindered secondary amine group and at least one tertiary amine or sterically hindered secondary amine group; wherein the primary or non-sterically hindered secondary amine and the nearest tertiary or sterically hindered secondary amine group are separated by a carbon chain including 3 or 4 carbon atoms and wherein the compound is a compound of Formula (I).

  一种从气流中捕集二氧化碳的过程，该过程包括将含二氧化碳的气流与包括以下化合物接触：一个一级或非立体阻碍的二级胺基和至少一个三级胺或立体阻碍的二级胺基；其中一级或非立体阻碍的二级胺和最近的三级或立体阻碍的二级胺基之间由包括3或4个碳原子的碳链分隔，并且该化合物是式（I）的化合物。
• US6656956B2
  申请人：——

  公开号：US6656956B2

  公开（公告）日：2003-12-02
• US9409122B2
  申请人：——

  公开号：US9409122B2

  公开（公告）日：2016-08-09
• Potent CCR4 antagonists: Synthesis, evaluation, and docking study of 2,4-diaminoquinazolines
  作者：Kazuhiro Yokoyama、Noriko Ishikawa、Susumu Igarashi、Noriyuki Kawano、Naoyuki Masuda、Kazuyuki Hattori、Takahiro Miyazaki、Shin-ichi Ogino、Masaya Orita、Yuzo Matsumoto、Makoto Takeuchi、Mitsuaki Ohta

  DOI：10.1016/j.bmc.2008.07.062

  日期：2008.9

  A series of CC chemokine receptor-4 (CCR4) antagonists were examined in a previous report in an attempt to improve metabolic stability in human liver microsomes. In this study, the cycloheptylamine moiety of N-cycloheptyl-6,7-dimethoxy-2-(4-pyrrolidin-1-ylpiperidin-1-yl)quinazolin-4-amine 1 was replaced with the p-chloroaniline moiety, and the resulting compound, N-(4-chlorophenyl)-6,7-dimethoxy-2-(4-pyrrolidin-1-ylpiperidin-1-yl)quinazolin-4-amine (8c), retained its potency ([S-35]GTP gamma S-binding inhibition and CCL22-induced chemotaxis in humans/mice). Based on the structure-activity relationships (SAR), a homology model was constructed for CCR4 to explain the binding mode of 8c. Overall, there was good agreement between the docking pose of the CCR4 homology model and the human [S-35] GTP gamma S assay results. Administration of 8c in a murine model of acute dermatitis showed anti-inflammatory activity (oxazolone-induced contact hypersensitivity test). (C) 2008 Elsevier Ltd. All rights reserved.